$IONS
IONIS PHARMACEUTICALS INC

2019 Q4 Form 10-K Financial Statement

#000114036120004500 Filed on March 02, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $493.7M $167.9M $163.8M
YoY Change 156.97% 15.47% 39.12%
Cost Of Revenue $1.000M $1.000M $1.364M
YoY Change -44.44%
Gross Profit $492.7M $166.9M $162.4M
YoY Change 158.91% 37.96%
Gross Profit Margin 99.8% 99.41% 99.17%
Selling, General & Admin $83.30M $60.00M $75.11M
YoY Change 26.02% -12.66% 13.46%
% of Gross Profit 16.91% 35.95% 46.24%
Research & Development $148.7M $104.4M $106.2M
YoY Change 31.01% 9.55% 4.32%
% of Gross Profit 30.18% 62.55% 65.37%
Depreciation & Amortization $4.000M $3.200M $3.600M
YoY Change 17.65% -3.03% 20.0%
% of Gross Profit 0.81% 1.92% 2.22%
Operating Expenses $232.0M $164.4M $75.11M
YoY Change 29.25% 0.24% 13.46%
Operating Profit $260.7M $2.523M -$18.83M
YoY Change 2317.47% -113.58% -62.56%
Interest Expense -$200.0K $1.100M $11.80M
YoY Change -184.62% 6.2%
% of Operating Profit -0.08% 43.6%
Other Income/Expense, Net -$400.0K -$100.0K -$45.00K
YoY Change -200.0%
Pretax Income $238.3M $3.500M -$16.94M
YoY Change 2106.48% -117.59% -69.87%
Income Tax $34.30M -$14.90M -$6.900M
% Of Pretax Income 14.39% -425.71%
Net Earnings $184.4M $26.16M -$876.0K
YoY Change -42.38% -673.88% -97.83%
Net Earnings / Revenue 37.36% 15.58% -0.53%
Basic Earnings Per Share $1.31 $0.19 -$0.01
Diluted Earnings Per Share $1.28 $0.18 -$0.01
COMMON SHARES
Basic Shares Outstanding 140.6M 140.6M 140.2M
Diluted Shares Outstanding 153.3M 143.4M 140.2M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.500B $2.221B $2.262B
YoY Change 19.94% 13.36% 14.22%
Cash & Equivalents $683.3M $247.9M $272.5M
Short-Term Investments $1.816B $1.973B $1.990B
Other Short-Term Assets $139.8M $118.8M $102.1M
YoY Change 36.46% 22.35% 32.56%
Inventory $18.20M $19.40M $18.50M
Prepaid Expenses
Receivables $63.00M $49.10M $31.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.721B $2.408B $2.414B
YoY Change 23.22% 15.82% 15.88%
LONG-TERM ASSETS
Property, Plant & Equipment $153.7M $161.7M $135.3M
YoY Change 16.26% 22.5% 5.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.63M $298.2M $25.78M
YoY Change 114.04% 2248.03% 102.98%
Total Long-Term Assets $512.5M $486.9M $463.5M
YoY Change 11.44% 188.62% 182.65%
TOTAL ASSETS
Total Short-Term Assets $2.721B $2.408B $2.414B
Total Long-Term Assets $512.5M $486.9M $463.5M
Total Assets $3.233B $2.895B $2.878B
YoY Change 21.19% 28.79% 28.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.07M $13.10M $15.63M
YoY Change -43.94% -3.68% 17.5%
Accrued Expenses $66.77M $79.10M $49.68M
YoY Change 40.56% 5.47% -32.5%
Deferred Revenue $118.3M $137.4M
YoY Change -26.2%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.50M
YoY Change 941.67%
Total Short-Term Liabilities $273.0M $231.8M $241.2M
YoY Change -2.6% -10.91% -2.97%
LONG-TERM LIABILITIES
Long-Term Debt $770.3M $656.7M $647.0M
YoY Change 21.69% 5.22% 3.57%
Other Long-Term Liabilities $505.3M $508.6M $532.4M
YoY Change -10.94% -2.83% -4.35%
Total Long-Term Liabilities $1.276B $1.165B $1.179B
YoY Change 6.26% 1.55% -0.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $273.0M $231.8M $241.2M
Total Long-Term Liabilities $1.276B $1.165B $1.179B
Total Liabilities $1.549B $1.559B $1.421B
YoY Change 4.59% 1.39% -8.42%
SHAREHOLDERS EQUITY
Retained Earnings -$707.5M -$883.7M
YoY Change -26.85%
Common Stock $2.204B $2.177B
YoY Change 7.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.471B $1.336B $1.269B
YoY Change
Total Liabilities & Shareholders Equity $3.233B $2.895B $2.878B
YoY Change 21.19% 28.79% 28.05%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $184.4M $26.16M -$876.0K
YoY Change -42.38% -673.88% -97.83%
Depreciation, Depletion And Amortization $4.000M $3.200M $3.600M
YoY Change 17.65% -3.03% 20.0%
Cash From Operating Activities $277.8M -$12.80M -$27.10M
YoY Change 140.52% -50.77% -105.42%
INVESTING ACTIVITIES
Capital Expenditures -$7.800M -$15.90M -$4.000M
YoY Change 457.14% 396.88% -40.3%
Acquisitions
YoY Change
Other Investing Activities $145.9M $17.30M -$106.7M
YoY Change -144.91% -105.68% -71.04%
Cash From Investing Activities $138.2M $1.400M -$110.7M
YoY Change -142.37% -100.45% -70.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $34.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.20M -13.20M 34.50M
YoY Change 97.94% -262.96% -92.38%
NET CHANGE
Cash From Operating Activities 277.8M -12.80M -27.10M
Cash From Investing Activities 138.2M 1.400M -110.7M
Cash From Financing Activities 19.20M -13.20M 34.50M
Net Change In Cash 435.2M -24.60M -103.3M
YoY Change -316.52% -92.44% -117.88%
FREE CASH FLOW
Cash From Operating Activities $277.8M -$12.80M -$27.10M
Capital Expenditures -$7.800M -$15.90M -$4.000M
Free Cash Flow $285.6M $3.100M -$23.10M
YoY Change 144.31% -113.6% -104.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
ions:LongTermObligationsNoncurrent
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000874015
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1816257000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1805252000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
25674000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
24032000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-21865000
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.08
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.07
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142872000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134056000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126098000
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
290796000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
118272000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
160256000
CY2019Q4 ions Long Term Obligations Noncurrent
LongTermObligationsNoncurrent
15543000
CY2018Q4 ions Long Term Obligations Noncurrent
LongTermObligationsNoncurrent
4914000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1471094000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1048079000
CY2019Q4 us-gaap Minority Interest
MinorityInterest
213453000
CY2018Q4 us-gaap Minority Interest
MinorityInterest
139081000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1684547000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1187160000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
346769000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-76156000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16763000
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 ions Period After Billing When Payment Is Received
PeriodAfterBillingWhenPaymentIsReceived
P3M
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
000-19125
CY2019 dei Entity Registrant Name
EntityRegistrantName
Ionis Pharmaceuticals, Inc.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0336973
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2855 Gazelle Court
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92010
CY2019 dei City Area Code
CityAreaCode
760
CY2019 dei Local Phone Number
LocalPhoneNumber
931-9200
CY2019 dei Security12b Title
Security12bTitle
Common Stock, $.001 Par Value
CY2019 dei Trading Symbol
TradingSymbol
IONS
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
7483343134
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
139219800
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
305557000
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2026000
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
13749000
CY2019 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
0
CY2018 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
0
CY2017 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
-7689000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2018 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
37338000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
33363000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
30920000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
461500000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
411900000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372500000
CY2017 ions Payments To Acquire Licenses And Other Assets
PaymentsToAcquireLicensesAndOtherAssets
3093000
CY2019 ions Payments To Acquire Cost Method Investments
PaymentsToAcquireCostMethodInvestments
10000000
CY2018 ions Payments To Acquire Cost Method Investments
PaymentsToAcquireCostMethodInvestments
0
CY2017 ions Payments To Acquire Cost Method Investments
PaymentsToAcquireCostMethodInvestments
2500000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8418000
CY2018 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
223000
CY2019 ions Increase Decrease In Accrued Liabilities And Deferred Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
16499000
CY2018 ions Increase Decrease In Accrued Liabilities And Deferred Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
-17023000
CY2017 ions Increase Decrease In Accrued Liabilities And Deferred Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
28564000
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
109500000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10428000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
296563000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139998000
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
32500000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
35200000
CY2017 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
374000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12600000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17200000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2000000.0
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
39613000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
346000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
119657000
CY2019 ions Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Redemption
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
77331000
CY2019 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
81877000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
56110000
CY2019 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-85860000
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1334000
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-67000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
22932000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85975000
CY2017 ions Stock Issued During Period Value New Issues By Subsidiary
StockIssuedDuringPeriodValueNewIssuesBySubsidiary
157270000
CY2017 ions Noncontrolling Interest Increase From New Issues By Subsidiary
NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
30000
CY2017 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-11224000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
365280000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
273741000
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-280000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
23000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
27900000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131312000
CY2018 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-58781000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1187160000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
294146000
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6633000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
93000
CY2019 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
34388000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146574000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
-19242000
CY2019 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
9118000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1684547000
CY2019 ions Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1542000
CY2018 ions Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
0
CY2017 ions Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
0
CY2019 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
0
CY2018 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
0
CY2017 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
3659000
CY2019 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2018 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2017 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
374000
CY2019 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
0
CY2018 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
0
CY2017 ions Gain Loss On Extinguishment Of Financing Liability
GainLossOnExtinguishmentOfFinancingLiability
-7689000
CY2019 ions Asset Impairment Charges Including Other Than Temporary Impairment In Cost Method Investments
AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
2034000
CY2018 ions Asset Impairment Charges Including Other Than Temporary Impairment In Cost Method Investments
AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
1012000
CY2017 ions Asset Impairment Charges Including Other Than Temporary Impairment In Cost Method Investments
AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
3302000
CY2017 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
9114000
CY2019 ions Payments To Acquire Licenses And Other Assets
PaymentsToAcquireLicensesAndOtherAssets
5377000
CY2018 ions Payments To Acquire Licenses And Other Assets
PaymentsToAcquireLicensesAndOtherAssets
4044000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.12
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
276868000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132320000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18792000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124016000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
276868000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132320000
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.09
CY2018 ions Incremental Common Shares Attributable To Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
6000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
276868000
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134056000
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.07
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18792000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
124016000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2017 ions Incremental Common Shares Attributable To Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
4000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
18792000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126098000
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.15
CY2019 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Amount
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
-16344000
CY2019 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Percent
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
-0.047
CY2018 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Amount
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
0
CY2018 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Percent
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
0.000
CY2017 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Amount
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
0
CY2017 ions Effective Income Tax Rate Reconciliation Impact From Outside Basis Differences Percent
EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
0.000
CY2019 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
-0.006
CY2018 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Amount
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
0
CY2017 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Amount
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
0
CY2017 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
0.000
CY2019 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Amount
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
-2071000
CY2019 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0
CY2018 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
0
CY2017 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
2507000
CY2019 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
12500000
CY2018 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
0
CY2017 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
3599000
CY2019 ions Payment To Settle Financing Liability For Leased Facility
PaymentToSettleFinancingLiabilityForLeasedFacility
0
CY2018 ions Payment To Settle Financing Liability For Leased Facility
PaymentToSettleFinancingLiabilityForLeasedFacility
0
CY2017 ions Payment To Settle Financing Liability For Leased Facility
PaymentToSettleFinancingLiabilityForLeasedFacility
80133000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100021000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
475865000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
229087000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
404467000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
149190000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
110438000
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2018 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2017 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
59750000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2018 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
50000000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2037000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
44945000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278820000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129630000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84685000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
683287000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278820000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129630000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
9870000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
9592000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
8035000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
9041000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14178000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2017 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 ions Non Cash Capital And Patent Expenditures
NonCashCapitalAndPatentExpenditures
3126000
CY2018 ions Non Cash Capital And Patent Expenditures
NonCashCapitalAndPatentExpenditures
4428000
CY2017 ions Non Cash Capital And Patent Expenditures
NonCashCapitalAndPatentExpenditures
1983000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2019Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2026000
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
13749000
CY2019Q4 ions Call Spread
CallSpread
52600000
CY2019Q4 us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
108700000
CY2019Q4 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
56100000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3350000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2019 us-gaap Notes Issued1
NotesIssued1
439326000
CY2018 us-gaap Notes Issued1
NotesIssued1
0
CY2017 us-gaap Notes Issued1
NotesIssued1
0
CY2019 us-gaap Notes Reduction
NotesReduction
375590000
CY2018 us-gaap Notes Reduction
NotesReduction
0
CY2017 us-gaap Notes Reduction
NotesReduction
0
CY2019Q4 ions Shares Received From Subsidiary For License Of Drug
SharesReceivedFromSubsidiaryForLicenseOfDrug
6900000
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.09
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
296563000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
139998000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.12
CY2019 ions Incremental Common Shares Attributable To Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
18000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
296563000
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
142872000
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.08
CY2019 ions Revenue From Contract With Customer Number Of Performance Obligations At Inception Of Contract
RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract
1
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3285000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3022000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2781000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2520000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2396000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
9465000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
23469000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6234000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
17235000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
3600000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
CY2017 us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-76156000
CY2019 ions Cost Of Products Sold Previously Recognized
CostOfProductsSoldPreviouslyRecognized
700000
CY2018 ions Cost Of Products Sold Previously Recognized
CostOfProductsSoldPreviouslyRecognized
100000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-76156000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16763000
CY2018 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
-0.116
CY2017 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
3987000
CY2017 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
-0.238
CY2019 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Amount
EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
0
CY2019 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Percent
EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
0.000
CY2018 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Amount
EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
59583000
CY2018 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Percent
EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
-0.782
CY2017 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Amount
EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
0
CY2017 ions Effective Income Tax Rate Reconciliation Drug Licensing Gain Percent
EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
0.000
CY2018 ions Effective Income Tax Rate Reconciliation Foreign Derived Intangible Income Benefit Percent
EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
0.000
CY2019Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
6110000
CY2018Q4 us-gaap Deferred Tax Liabilities Financing Arrangements
DeferredTaxLiabilitiesFinancingArrangements
24018000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
32019000
CY2019Q1 ions Shares Received From Subsidiary For License Of Drug
SharesReceivedFromSubsidiaryForLicenseOfDrug
2800000
CY2019Q4 ions Shares Received From Subsidiary For License Of Drug
SharesReceivedFromSubsidiaryForLicenseOfDrug
6900000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk</div> <div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody’s, Standard &amp; Poor’s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div>
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2200000
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
800000
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
800000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
CY2019 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
1400000
CY2018 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
300000
CY2017 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2018Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Cost
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost
1874529000
CY2018Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Gain
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain
556000
CY2018Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni Gross Unrealized Loss
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss
4068000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
39300000
CY2018Q4 ions Debt Securities Available For Sale And Equity Securities Fv Ni
DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi
1871017000
CY2019Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
113
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
375944000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
255000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
59184000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
41000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
435128000
CY2019Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
296000
CY2019Q4 ions Long Term Debt And Other Obligations
LongTermDebtAndOtherObligations
787526000
CY2018Q4 ions Long Term Debt And Other Obligations
LongTermDebtAndOtherObligations
646720000
CY2019Q4 ions Long Term Debt And Other Obligations Noncurrent
LongTermDebtAndOtherObligationsNoncurrent
785500000
CY2018Q4 ions Long Term Debt And Other Obligations Noncurrent
LongTermDebtAndOtherObligationsNoncurrent
632971000
CY2019Q4 ions Debt Instrument Convertible Conversion Price Including Call Spread
DebtInstrumentConvertibleConversionPriceIncludingCallSpread
123.38
CY2019 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
-37300000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
3900000
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122599000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
756716000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
365883000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
599674000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
661046000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-61372000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
514179000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
483132000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
31047000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
346769000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16763000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
346769000
CY2019 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
0
CY2019 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Percent
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
0.000
CY2018 ions Effective Income Tax Rate Reconciliation Expiration Of Net Operating Loss Amount
EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
8864000
CY2019 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Amount
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
0
CY2019 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Percent
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
0.000
CY2018 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Amount
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
0
CY2018 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Percent
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
0.000
CY2017 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Amount
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
469000
CY2017 ions Effective Income Tax Rate Reconciliation Deconsolidation Adjustment For Subsidiary At Ipo Percent
EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
-0.028
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
210455000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
313652000
CY2018Q4 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
332100000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
197000000.0
CY2019 ions Increase Decrease In State Tax Liability
IncreaseDecreaseInStateTaxLiability
-59100000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
21700000
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q1 ions Sublicense Fee Paid For License Of Drug
SublicenseFeePaidForLicenseOfDrug
75000000
CY2019Q1 ions Receipt Of Shares In Subsidiary
ReceiptOfSharesInSubsidiary
2800000
CY2019Q4 us-gaap Assets
Assets
3233112000
CY2018Q4 us-gaap Assets
Assets
2667784000
CY2019 ions Defined Contribution Plan Employee Contribution Limit By Plan Participants Under Fifty Years Age
DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge
19000
CY2019 ions Defined Contribution Plan Employee Contribution Limit By Plan Participants Over Fifty Years Age
DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge
25000
CY2019Q1 us-gaap Revenues
Revenues
297214000
CY2019Q2 us-gaap Revenues
Revenues
163813000
CY2019Q3 us-gaap Revenues
Revenues
167892000
CY2019Q4 us-gaap Revenues
Revenues
493680000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
175679000
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
182640000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
165369000
CY2019Q4 us-gaap Costs And Expenses
CostsAndExpenses
233028000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
121535000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18827000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2523000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
260652000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
90884000
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-10012000
CY2019Q3 us-gaap Profit Loss
ProfitLoss
18432000
CY2019Q4 us-gaap Profit Loss
ProfitLoss
203957000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
84443000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-876000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26163000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
184415000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.63
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.62
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28
CY2018Q1 us-gaap Revenues
Revenues
144419000
CY2018Q2 us-gaap Revenues
Revenues
117747000
CY2018Q3 us-gaap Revenues
Revenues
145395000
CY2018Q4 us-gaap Revenues
Revenues
192113000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
147720000
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
168028000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
163967000
CY2018Q4 us-gaap Costs And Expenses
CostsAndExpenses
181331000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3301000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-50281000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18572000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
10782000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-10812000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-56573000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-20365000
CY2018Q4 us-gaap Profit Loss
ProfitLoss
302735000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1420000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-40358000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4559000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
320078000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137699000
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2019Q3 ions Incremental Common Shares Attributable To Dilutive Effect Of Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
20000
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2018Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.21
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
87543000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138582000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.63
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-933000
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140247000
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26158000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140551000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
183795000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140583000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1212000
CY2018Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125330000
CY2018Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-37932000
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128712000
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4563000
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137346000
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
319694000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
87543000
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
138582000
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.63
CY2019Q1 ions Incremental Common Shares Attributable To Dilutive Effect Of Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
38000
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
87543000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
141537000
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.62
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26158000
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140551000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
26158000
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
143408000
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
183795000
CY2019Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
140583000
CY2019Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
CY2019Q4 ions Incremental Common Shares Attributable To Dilutive Effect Of Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
18000
CY2019Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
196485000
CY2019Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
153303000
CY2019Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.28
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
319694000
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
137699000
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2018Q4 ions Incremental Common Shares Attributable To Dilutive Effect Of Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
7000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
330439000
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149856000
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.21

Files In Submission

Name View Source Status
0001140361-20-004500-index-headers.html Edgar Link pending
0001140361-20-004500-index.html Edgar Link pending
0001140361-20-004500.txt Edgar Link pending
0001140361-20-004500-xbrl.zip Edgar Link pending
exhibit10_70.htm Edgar Link pending
exhibit21_1.htm Edgar Link pending
exhibit23_1.htm Edgar Link pending
exhibit31_1.htm Edgar Link pending
exhibit31_2.htm Edgar Link pending
exhibit32_1.htm Edgar Link pending
exhibit4_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10k_htm.xml Edgar Link completed
image1.jpg Edgar Link pending
image10.jpg Edgar Link pending
image11.jpg Edgar Link pending
image12.jpg Edgar Link pending
image13.jpg Edgar Link pending
image14.jpg Edgar Link pending
image15.jpg Edgar Link pending
image16.jpg Edgar Link pending
image17.jpg Edgar Link pending
image2.jpg Edgar Link pending
image3.jpg Edgar Link pending
image4.jpg Edgar Link pending
image5.jpg Edgar Link pending
image6.jpg Edgar Link pending
image7.jpg Edgar Link pending
image8.jpg Edgar Link pending
image9.jpg Edgar Link pending
ions-20191231.xsd Edgar Link pending
ions-20191231_cal.xml Edgar Link unprocessable
ions-20191231_def.xml Edgar Link unprocessable
ions-20191231_lab.xml Edgar Link unprocessable
ions-20191231_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending